Current Liabilities decreased faster than Relmada Therapeutics Inc's Cash & cash equivalent, this led to improvement in Relmada Therapeutics Inc's Quick Ratio to 21.72, above Relmada Therapeutics Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 29 other companies have achieved higher Quick Ratio than Relmada Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 266, from total ranking in the first quarter 2026 at 607.

Explain Quick Ratio?
How much Cash & cash equivalents RLMD�s has?
What are RLMD�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/RLMD/financial-strength

https://api.csimarket.com/api/v1/companies/RLMD/fundamentals

https://api.csimarket.com/api/v1/companies/RLMD/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

RLMD Quick Ratio	(Jun 30 2026) Q2	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) 2025	(Jun 30 2025) Q2
Y / Y Current Liabilities Change	95.21 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	955.95 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	21.72	Subscribe	Subscribe	Subscribe	Subscribe
RLMD's Total Ranking	# 266	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-22.25 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	-6.94 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio second quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 30
Healthcare Sector	# 48
Overall Market	# 202

Quick Ratio Statistics
High	Average	Low
79.87	8.73	0.03
(Dec 31 2019)		(May 31 2013)

Financial Statements
Relmada Therapeutics Inc's Current Liabilities	$ 10 Millions	Visit RLMD's Balance sheet
Relmada Therapeutics Inc's Cash & cash equivalent	$ 218 Millions	Visit RLMD's Balance sheet
Source of RLMD's Sales		Visit RLMD's Sales by Geography

Cumulative Relmada Therapeutics Inc's Quick Ratio

RLMD's Quick Ratio for the trailling 12 Months

RLMD Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	31.6 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	280.75 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	14.77	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 1929	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	14.84 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	54.53 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to RLMD Financial Strength Comparisons >> Go to Compare RLMD Quick Ratio to its Competitors

On the trailing twelve months basis RLMD Cash & cash equivalent more than doubled by 955.95 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Relmada Therapeutics Inc's Quick Ratio to 14.77, above RLMD average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 438 other companies have achieved higher Quick Ratio than Relmada Therapeutics Inc. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3223.

Explain Quick Ratio?
How much Cash & cash equivalents RLMD�s has?
What are RLMD�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 439
Healthcare Sector	# 899
Within the Market	#

trailing twelve months Quick Ratio Statistics
High	Average	Low
8.18	1.7	0.21
(Jun 30 2020)		(Sep 30 2024)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Avalyn Pharma Inc	49.93	$ 539.733 Millions	$ 10.809 Millions
Pasithea Therapeutics Corp	49.76	$ 91.464 Millions	$ 1.838 Millions
Disc Medicine Inc	44.03	$ 1,336.770 Millions	$ 30.360 Millions
Trevi Therapeutics Inc	36.50	$ 318.870 Millions	$ 8.736 Millions
Design Therapeutics Inc	35.76	$ 401.889 Millions	$ 11.240 Millions
Mineralys Therapeutics Inc	34.87	$ 673.704 Millions	$ 19.319 Millions
Praxis Precision Medicines Inc	34.32	$ 1,683.790 Millions	$ 49.058 Millions
Agios Pharmaceuticals Inc	33.94	$ 2,383.112 Millions	$ 70.217 Millions
Mbx Biosciences Inc	33.10	$ 783.099 Millions	$ 23.660 Millions
Xbiotech Inc	32.67	$ 109.528 Millions	$ 3.353 Millions
Avalo Therapeutics Inc	31.89	$ 787.143 Millions	$ 24.682 Millions
Fulcrum Therapeutics Inc	30.96	$ 318.840 Millions	$ 10.298 Millions
Climb Bio Inc	30.86	$ 183.123 Millions	$ 5.934 Millions
Indaptus Therapeutics Inc	29.61	$ 15.554 Millions	$ 0.525 Millions
Crinetics Pharmaceuticals Inc	29.41	$ 2,350.275 Millions	$ 79.915 Millions
Spyre Therapeutics Inc	28.48	$ 1,100.000 Millions	$ 38.620 Millions
Curanex Pharmaceuticals Inc	28.17	$ 2.938 Millions	$ 0.104 Millions
Onkure Therapeutics Inc	28.04	$ 186.284 Millions	$ 6.643 Millions
Ligand Pharmaceuticals Incorporated	27.33	$ 1,277.438 Millions	$ 46.736 Millions
Shattuck Labs Inc	26.94	$ 208.300 Millions	$ 7.731 Millions
Cryoport inc	26.87	$ 785.860 Millions	$ 29.244 Millions
Roivant Sciences Ltd	26.82	$ 7,607.076 Millions	$ 283.603 Millions
Neuphoria Therapeutics Inc	26.26	$ 19.866 Millions	$ 0.757 Millions
Palvella Therapeutics Inc	26.23	$ 313.381 Millions	$ 11.947 Millions
Upstream Bio Inc	26.16	$ 261.307 Millions	$ 9.988 Millions
Rallybio Corporation	26.02	$ 92.800 Millions	$ 3.567 Millions
Assembly Biosciences Inc	25.95	$ 608.475 Millions	$ 23.445 Millions
Immix Biopharma Inc	25.49	$ 238.715 Millions	$ 9.364 Millions
Boundless Bio Inc	25.00	$ 194.230 Millions	$ 7.768 Millions
Sionna Therapeutics Inc	24.88	$ 268.300 Millions	$ 10.782 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.